249 related articles for article (PubMed ID: 32181877)
1. Development and validation of a five-gene model to predict postoperative brain metastasis in operable lung adenocarcinoma.
Fu F; Zhang Y; Gao Z; Zhao Y; Wen Z; Han H; Li Y; Chen H
Int J Cancer; 2020 Jul; 147(2):584-592. PubMed ID: 32181877
[TBL] [Abstract][Full Text] [Related]
2. Proteomics-based Model for Predicting the Risk of Brain Metastasis in Patients with Resected Lung Adenocarcinoma carrying the EGFR Mutation.
Deng Q; Wang F; Song L; Chen L; Huang Y; Guo Z; Yang H
Int J Med Sci; 2024; 21(4):765-774. PubMed ID: 38464823
[No Abstract] [Full Text] [Related]
3. Eight-gene signature predicts recurrence in lung adenocarcinoma.
Zhang Y; Fan Q; Guo Y; Zhu K
Cancer Biomark; 2020; 28(4):447-457. PubMed ID: 32508318
[TBL] [Abstract][Full Text] [Related]
4. Integrated bioinformatics analysis reveals CDK1 and PLK1 as potential therapeutic targets of lung adenocarcinoma.
Li S; Li H; Cao Y; Geng H; Ren F; Li K; Dai C; Li N
Medicine (Baltimore); 2021 Aug; 100(32):e26474. PubMed ID: 34397869
[TBL] [Abstract][Full Text] [Related]
5. Identification Six Metabolic Genes as Potential Biomarkers for Lung Adenocarcinoma.
Zhang S; Lu Y; Liu Z; Li X; Wang Z; Cai Z
J Comput Biol; 2020 Oct; 27(10):1532-1543. PubMed ID: 32298601
[TBL] [Abstract][Full Text] [Related]
6. Development of metastasis-associated seven gene signature for predicting lung adenocarcinoma prognosis using single-cell RNA sequencing data.
He J; Zhang W; Li F; Yu Y
Math Biosci Eng; 2021 Jul; 18(5):5959-5977. PubMed ID: 34517518
[TBL] [Abstract][Full Text] [Related]
7. Genome‑wide investigation of the clinical significance and prospective molecular mechanisms of kinesin family member genes in patients with lung adenocarcinoma.
Zhang L; Zhu G; Wang X; Liao X; Huang R; Huang C; Huang P; Zhang J; Wang P
Oncol Rep; 2019 Sep; 42(3):1017-1034. PubMed ID: 31322267
[TBL] [Abstract][Full Text] [Related]
8. Prognostic and predictive values of CDK1 and MAD2L1 in lung adenocarcinoma.
Shi YX; Zhu T; Zou T; Zhuo W; Chen YX; Huang MS; Zheng W; Wang CJ; Li X; Mao XY; Zhang W; Zhou HH; Yin JY; Liu ZQ
Oncotarget; 2016 Dec; 7(51):85235-85243. PubMed ID: 27835911
[TBL] [Abstract][Full Text] [Related]
9. The value of CEP55 gene as a diagnostic biomarker and independent prognostic factor in LUAD and LUSC.
Fu L; Wang H; Wei D; Wang B; Zhang C; Zhu T; Ma Z; Li Z; Wu Y; Yu G
PLoS One; 2020; 15(5):e0233283. PubMed ID: 32437446
[TBL] [Abstract][Full Text] [Related]
10. Overexpression of KIF18A promotes cell proliferation, inhibits apoptosis, and independently predicts unfavorable prognosis in lung adenocarcinoma.
Zhong Y; Jiang L; Lin H; Li X; Long X; Zhou Y; Li B; Li Z
IUBMB Life; 2019 Jul; 71(7):942-955. PubMed ID: 30817091
[TBL] [Abstract][Full Text] [Related]
11. A novel strategy of integrated microarray analysis identifies CENPA, CDK1 and CDC20 as a cluster of diagnostic biomarkers in lung adenocarcinoma.
Liu WT; Wang Y; Zhang J; Ye F; Huang XH; Li B; He QY
Cancer Lett; 2018 Jul; 425():43-53. PubMed ID: 29608985
[TBL] [Abstract][Full Text] [Related]
12. Single-cell transcriptome analysis demonstrates inter-patient and intra-tumor heterogeneity in primary and metastatic lung adenocarcinoma.
Liu Y; Ye G; Huang L; Zhang C; Sheng Y; Wu B; Han L; Wu C; Dong B; Qi Y
Aging (Albany NY); 2020 Nov; 12(21):21559-21581. PubMed ID: 33170151
[TBL] [Abstract][Full Text] [Related]
13. Identification of 5-Gene Signature Improves Lung Adenocarcinoma Prognostic Stratification Based on Differential Expression Invasion Genes of Molecular Subtypes.
Zheng Z; Deng W; Yang J
Biomed Res Int; 2020; 2020():8832739. PubMed ID: 33490259
[TBL] [Abstract][Full Text] [Related]
14. Identification of theranostic factors for patients developing metastasis after surgery for early-stage lung adenocarcinoma.
Cheng WC; Chang CY; Lo CC; Hsieh CY; Kuo TT; Tseng GC; Wong SC; Chiang SF; Huang KC; Lai LC; Lu TP; Chao KSC; Sher YP
Theranostics; 2021; 11(8):3661-3675. PubMed ID: 33664854
[No Abstract] [Full Text] [Related]
15. Unique metastasis-associated lncRNA signature optimizes prediction of tumor relapse in lung adenocarcinoma.
Zhang X; Han J; Du L; Li X; Hao J; Wang L; Zheng G; Duan W; Xie Y; Zhao Y; Zhang X; Zou M; Wang C
Thorac Cancer; 2020 Mar; 11(3):728-737. PubMed ID: 31994347
[TBL] [Abstract][Full Text] [Related]
16. Development and validation of a novel epigenetic-related prognostic signature and candidate drugs for patients with lung adenocarcinoma.
Wang Z; Embaye KS; Yang Q; Qin L; Zhang C; Liu L; Zhan X; Zhang F; Wang X; Qin S
Aging (Albany NY); 2021 Jul; 13(14):18701-18717. PubMed ID: 34285141
[TBL] [Abstract][Full Text] [Related]
17. Co-expression network analysis identified KIF2C in association with progression and prognosis in lung adenocarcinoma.
Bai Y; Xiong L; Zhu M; Yang Z; Zhao J; Tang H
Cancer Biomark; 2019; 24(3):371-382. PubMed ID: 30883337
[TBL] [Abstract][Full Text] [Related]
18. Establishment and validation of an immune-associated signature in lung adenocarcinoma.
Wang Z; Chen X
Int Immunopharmacol; 2020 Nov; 88():106867. PubMed ID: 32799112
[TBL] [Abstract][Full Text] [Related]
19. A seven-long noncoding RNA signature predicts relapse in patients with early-stage lung adenocarcinoma.
Zhou H; Zhang H; Chen J; Cao J; Liu L; Guo C; Huang G; Zeng D
J Cell Biochem; 2019 Sep; 120(9):15730-15739. PubMed ID: 31050375
[TBL] [Abstract][Full Text] [Related]
20. A large cohort study identifying a novel prognosis prediction model for lung adenocarcinoma through machine learning strategies.
Li Y; Ge D; Gu J; Xu F; Zhu Q; Lu C
BMC Cancer; 2019 Sep; 19(1):886. PubMed ID: 31488089
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
